The Hydropothecary Corp. is one of the best cannabis plays for investors, Echelon Wealth says

The Hydropothecary Corp. (The Hydropothecary Corp. Stock Quote, Chart, News: TSXV:THCX) is uniquely positioned as a low cost producer with strong value-added product capabilities, Echelon Wealth Partners analyst Russell Stanley says.

In a research report to clients today, Stanley initiated coverage of THCX with a “Speculative Buy” rating and a one-year price target of $5.50, implying a return of 40 per cent at the time of publication.

Stanley says Gatineau based Hydropothecary has what it takes to succeed in the nascent but already competitive sector.

“We expect the forthcoming dramatic increase in the industry’s cultivation capacity to commoditize dried cannabis production,” the analyst says. “In combination with government owned, centralized distribution models in Canada’s core recreational markets, many producers will struggle in an increasingly competitive environment. We believe the best plays for investors are companies with ultra-low cost production capability and/or demonstrated strength in developing and commercializing value-added products. Based on cash costs of finished goods inventory, THCX has reduced its product cost to $0.89/gram as of last quarter, down from $1.79/gram y/y. The Company also generates 40%+ of its revenue from value-added products, two of which won first and third place, respectively, at Lift’s Canadian Cannabis Awards in November 2017. We understand that vape pens, prerolls, and topicals are priorities for product development.”

Stanley thinks THCX will generate Adjusted EBITDA of negative $12.8-million on revenue of $11.4-million in fiscal 2018. He expects those numbers will improve to EBITDA of positive $15.0-million on a topline of $97.1-million the following year.

“Our central thesis continues to be that increasing supply and centralized purchasing by government-owned distributors in core markets will pressure pricing for dried cannabis over time,” Stanley adds. “From the government’s perspective, squeezing out the illicit market requires low pricing, without pricing product so low that it effectively encourages cannabis use.”

Tagged with: thcx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

Microsoft is starting to get AI, this investor says

Harris Douglas Asset Management portfolio manager Paul Harris says Microsoft (Microsaft Stock Quote, Chart, News, Analysts, Financials NASDAQ:MSFT) remains deeply… [Read More]

3 hours ago

Should you sell your Tilray stock?

Haywood Securities analyst Neal Gilmer says Tilray Brands’ (Tilray Brands Stock Quote, Chart, News, Analysts, Financials TSX:TLRY) fiscal Q1 results… [Read More]

3 days ago

KITS Eyecare is the right stock for price-sensitive times, analyst says

Haywood Securities analyst Gianluca Tucci says KITS Eyecare’s (KITS Eyecare Stock Quote, Chart, News, Analysts, Financials TSX:KITS) Q3 pre-release confirmed… [Read More]

3 days ago

This analyst just cut his price target on Telus

Desjardins Securities analyst Jerome Dubreuil lowered his target on Telus (Telus Stock Quote, Chart, News, Analysts, Financials TSX:T) to $13.00… [Read More]

4 days ago

This analyst just cut his price target on BCE

National Bank Financial analyst Adam Shine says BCE’s (BCE Stock Quote, Chart, News, Analysts, Financials TSX:BCE) near-term setup depends on… [Read More]

5 days ago

Is it time to sell your Wildbrain stock?

RBC Dominion Securities analyst Drew McReynolds says WildBrain (WildBrain Stock Quote, Chart, News, Analysts, Financials TSX:WILD) now has a clearer… [Read More]

5 days ago